摘要
Drug-induced kidney injury (DIKI) has a high incidence and increases the risk of chronic kidney disease and mortality. Although DIKI poses a serious threat to public health in China, the condition is preventable and controllable. To enhance awareness and standardize protocols for risk screening, early identification, diagnosis, prevention, and treatment, the Chinese Society of Clinical Pharmacy and the Chinese Society of Renal Diseases convened a multidisciplinary panel of experts to establish an editorial committee responsible for developing the Guideline for the Diagnosis, Treatment, and Management of Drug-Induced Kidney Injury. Based on a systematic search and evaluation of national and international guidelines, consensus statements, and research evidence, and taking into account China's tiered healthcare delivery framework and clinical practice experience, the committee developed this guideline through rigorous discussion and extensive consultation with specialists in pharmacy, nephrology, cardiology, and related fields. The guideline addresses the definition and classification of DIKI, common causative drugs, risk factors, diagnosis and severity assessment, prevention, treatment, prognosis, and follow-up management. It also establishes actionable risk identification and prevention workflows, monitoring frequencies, referral criteria, and key points for patient education suitable for implementation in primary care settings. Finally, the guideline provides a reference for the standardized management of DIKI among clinicians, pharmacists, nurses, technicians, and other relevant personnel, thereby improving the standard of DIKI management in China.